GLSI (Greenwich LifeSciences) Tax Expense: $0.00 Mil (TTM As of Mar. 2026)


GLSI Greenwich LifeSciences Inc GLSI
33 GF Score
Price $21.89
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Tax Expense?

Greenwich LifeSciences GLSI -7.17% 33 Tax Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Greenwich LifeSciences's tax expense for the months ended in Mar. 2026 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.


Greenwich LifeSciences  (NAS:GLSI) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Greenwich LifeSciences Tax Expense Related Terms


Greenwich LifeSciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences Tax Expense Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GLSI
33GF Score
Greenwich LifeSciences Inc GLSI
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.00 Mil mean?
Greenwich LifeSciences (GLSI) has a Tax Expense of $0.00 Mil as of Mar. 2026. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Greenwich LifeSciences and its competitors.
Is Greenwich LifeSciences' Tax Expense too high?
Greenwich LifeSciences' current Tax Expense is $0.00 Mil. Overall, Greenwich LifeSciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Tax Expense compare to SABS and SRZN?
Greenwich LifeSciences' Tax Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Tax Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Tax Expense of $0.00 Mil. The current Tax Expense is $0.00 Mil. Greenwich LifeSciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Tax Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
33GF Score

Get the complete analysis for GLSI

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.89
Price